Focusing on blood, breast and lung cancers, our specialists deliver exciting findings from the latest phase III trials. They explain keys to predicting disease progression; illuminate the roles of new therapies, including bispecific antibodies and antibody-drug conjugates; and discuss serious adverse effects, such as cytokine release syndrome and pneumonitis. Learn about T-DXd (now the standard for nonresectable or metastatic HER2), tailoring lung cancer management through neoadjuvant therapies, and more. Bonus: practical considerations for matching patients to treatment plans.
John Muir Health Presenters:
Thoracic medical oncologist
Dr. Matthew Gubens is a thoracic oncologist, or lung cancer specialist.
Dr. Laura Huppert is an oncologist who cares for patients with all stages of breast cancer.
Colorectal and gastrointestinal cancer specialist
Dr. Andrew H. Ko is a specialist in colorectal and gastrointestinal cancers, with a particular focus on pancreatic cancer.
A leading expert in hematology-oncology, Dr. Thomas Martin is associate director of UCSF's myeloma program and director of the unrelated donor transplantation programs for adults at UCSF Medical Center.